Cellectis (CLLS) Now Covered by William Blair
William Blair initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating on the biotechnology company’s stock.
A number of other equities research analysts have also issued reports on CLLS. Zacks Investment Research raised shares of Cellectis from a hold rating to a buy rating and set a $25.00 target price for the company in a research note on Friday, November 16th. ValuEngine lowered shares of Cellectis from a buy rating to a hold rating in a research note on Friday, November 16th. BidaskClub lowered shares of Cellectis from a sell rating to a strong sell rating in a research note on Wednesday, November 21st. Oppenheimer set a $44.00 target price on shares of Cellectis and gave the company a buy rating in a research note on Sunday, November 25th. Finally, Goldman Sachs Group started coverage on shares of Cellectis in a research note on Wednesday, December 19th. They set a neutral rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. Cellectis presently has a consensus rating of Hold and a consensus target price of $32.00.
Shares of NASDAQ:CLLS opened at $19.31 on Wednesday. The firm has a market cap of $792.48 million, a price-to-earnings ratio of -10.01 and a beta of 1.76. Cellectis has a 12-month low of $15.34 and a 12-month high of $38.85.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Further Reading: What is the return on assets formula?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.